Administrative Council for Economic Defense approved the acquisition of a set of medicines from Takeda Pharmaceuticals International by Hypera on the 20t of January. The deal involves the holding and commercialization, by Hypera, of product lines such as Dramin, Nebacetin, Neosaldina, Eparema, Xantinon, Nenê-Dent, Albocresil, Venalot, Ad-Til, Alektos and Nesina. The endorsement of the operation was conditioned to the signing of an agreement, which removes competitive concerns.